Antibacterial peptide NyAmp-a and application thereof

By providing the amino acid sequence of the antimicrobial peptide NyAmp-a, the problems of antibiotic resistance and strong cytotoxicity of antimicrobial peptides are solved, achieving effective antibacterial effects against a variety of bacteria and simplifying the formulation process.

CN121574209BActive Publication Date: 2026-09-15HONGHE UNIVERSITY
2 Cites 0 Cited by

Patent Information

Application Number
CN202511777017.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-11-28
Publication Date
2026-09-15
Estimated Expiration
2045-11-28

AI Technical Summary

Technical Problem

Existing antibiotics are prone to inducing drug resistance, and their antimicrobial peptides are highly cytotoxic and lack selectivity for specific strains.

Method used

An antimicrobial peptide NyAmp-a is provided, the amino acid sequence of which is shown in SEQ ID NO.1, for use in preparing antimicrobial products that inhibit Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Aeromonas hydrophila.

Benefits of technology

The antimicrobial peptide NyAmp-a has a minimum inhibitory concentration (MIC) of 25 μg/mL against Staphylococcus aureus, Bacillus subtilis, and Escherichia coli, and a MIC of 50 μg/mL against Aeromonas hydrophila, exhibiting significant antibacterial effects and being less likely to induce drug resistance, thus simplifying the formulation process.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses an antibacterial peptide NyAmp-a and application thereof, and relates to the technical field of biological medicine. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO. 1. The application further provides application of the antibacterial peptide NyAmp-a in preparation of antibacterial products for inhibiting Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Aeromonas hydrophila, and minimum inhibitory concentrations of the antibacterial peptide NyAmp-a to the bacteria. The application provides a novel and efficient antibacterial solution for the four common pathogenic bacteria, i.e., Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Aeromonas hydrophila. The antibacterial peptide NyAmp-a has the characteristics of not being prone to drug resistance, and the related antibacterial composition can be applied to the fields of medicine, agriculture, food and the like, has important practical application value, and effectively solves the problems of traditional antibiotics being prone to drug resistance, and the existing antibacterial peptides having strong cytotoxicity and lacking selectivity for specific bacterial strains.
Need to check novelty before this filing date? Find Prior Art